Celldex Therapeutics, Inc.
No SEC Form 4 filings for $CLDX in the last 30 days.
See all $CLDX insider activity →T. Rowe Price Associates, Inc. filed a Schedule 13G reporting beneficial ownership of Celldex Therapeutics Inc. common stock. It reported 4,686,187 shares, or 6.0% of the class, with sole voting power over 4,683,226 shares and sole dispositive power over 4,686,187 shares, according to the filing.
Biotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui
Celldex Therapeutics (CLDX) shares rose 10.7% after the company reported Q2 2026 revenue of $22,000 and a net loss of $73.5 million, with a wider first-half net loss of $152.19 million. The firm also updated investors on Phase 1 CDX-622 data and continued Phase 3 progress for barzolvolimab, while discontinuing a prurigo nodularis program.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CLDX (Celldex Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent CLDX coverage spans financial news, market movers and earnings.
The filing signals a new or updated institutional ownership position near a meaningful 6% threshold, but it does not indicate control or a near-term corporate action.
This is more of a pipeline catalyst framing than a single new data print, so follow-through depends on what investors expect from upcoming readouts.
The stock move is tied to continued barzolvolimab Phase 3 momentum despite worsening losses and minimal revenue.
The print is a mixed earnings signal: EPS beat but extreme revenue miss, leaving near-term direction dependent on management commentary and updated estimate revisions.
The filing adds concrete clinical and regulatory timing signals (Phase 3 topline in Sept/Oct 2026, BLA planned for 2027) plus a Phase 2 discontinuation in prurigo nodularis.
alphai scores every news story that mentions CLDX with an AI model for sentiment and relevance, and aggregates insider trades from Celldex Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
T. Rowe Price Associates, Inc. filed a Schedule 13G reporting beneficial ownership of Celldex Therapeutics Inc. common stock. It reported 4,686,187 shares, or 6.0% of the class, with sole voting power over 4,683,226 shares and sole dispositive power over 4,686,187 shares, according to the filing.
2 min readBiotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui
2 min readCelldex Therapeutics (CLDX) shares rose 10.7% after the company reported Q2 2026 revenue of $22,000 and a net loss of $73.5 million, with a wider first-half net loss of $152.19 million. The firm also updated investors on Phase 1 CDX-622 data and continued Phase 3 progress for barzolvolimab, while discontinuing a prurigo nodularis program.
4 min readCelldex Therapeutics (CLDX) reported Q2 adjusted EPS loss of $0.94 per share, better than the Zacks Consensus Estimate of a $1.04 loss. Revenue was $0.02 million, far below the consensus estimate, down from $0.73 million a year earlier. The article cites a Zacks Rank #2 (Buy) and upcoming consensus outlook of -$1.07 EPS on $1.86 million revenue for the next quarter.
2 min readCelldex Therapeutics, Inc. (CLDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Celldex Reports Second Quarter Financial Results and Provides Corporate Update Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submis
6 min readCelldex Therapeutics (CLDX) shares rose about 7.9% after the company reported topline Phase 2 results for prurigo nodularis in July 2026. The update is framed as supporting its dermatology pipeline and could affect expectations for future programs, with the next major catalyst cited as late-2026 Phase 3 EMBARQ-CSU.
6 min readThe article reviews pharma news. Halozyme Therapeutics said it signed a licensing deal with Incyte for INCA033989. Samsung Biologics plans to buy Swiss firm PolyPeptide for about $1.8 billion. Celldex reported mixed barzolvolimab results in prurigo nodularis and will stop that program. Sanofi will discontinue amlitelimab development in atopic dermatitis.
6 min readSimply Wall St discusses Celldex Therapeutics (CLDX) after it reported Phase 2 topline results for prurigo nodularis and announced CFO Sam Martin will retire around March 31, 2027. The piece links the data to barzolvolimab’s dermatology potential and notes valuation and funding risks amid ongoing losses and equity raises.
6 min readBiotech weekly roundup highlights EU approval for AstraZeneca’s Etcamah plus CDK4/6 inhibitors in ESR1-mutant ER+/HER2- advanced breast cancer, and accelerated FDA approval for GSK’s Jideytro in ROS1+ NSCLC. J&J received FDA De Novo for OTTAVA and reported Phase 3 PFS/OS gains for Talvey combos. Other items include deals (RGEN-BioLife, RPRX royalty buy) and trial updates for LLY, CLDX, and others.
7 min readCelldex Therapeutics said its 24-week, double-blind, placebo-controlled prurigo nodularis trial of barzolvolimab (140 patients) failed to meet the primary 12-week itch improvement endpoint and key secondary lesion outcomes. Mast cell depletion via reduced tryptase occurred, but symptoms did not improve. Celldex also previously halted EoE development. CLDX shares were down 6.06% premarket at $33.50.
3 min read
